COFEPRISComisión Federal para la Protección contra Riesgos Sanitarios (Mexico)

COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) is Mexico's federal regulatory authority for medicines, medical devices, food, cosmetics, pesticides, tobacco + occupational + environmental health risks. COFEPRIS is a decentralized organ of the Secretaría de Salud, established by Presidential Decree of 5 July 2001 + operating under the authority of the Ley General de Salud (LGS — General Health Law). COFEPRIS's headquarters is in Mexico City, with regional offices across Mexico's 32 federal entities + approximately 2,400 staff.

The COFEPRIS ecosystem includes:

• Comisión de Autorización Sanitaria (CAS) — drug + device + cosmetic + food marketing authorisations + clinical-trial authorisations.
• Comisión de Operación Sanitaria (COS) — inspection, sanitary verification + enforcement; GMP / GDP inspectorate.
• Comisión de Evidencia y Manejo de Riesgos (CEMAR) — risk evaluation, scientific advice + pharmacovigilance signal management.
• Comisión de Fomento Sanitario (CFS) — regulatory promotion, outreach + industry engagement.
• Comisión de Control Analítico y Ampliación de Cobertura (CCAYAC) — federal control laboratory + analytical reference + lot release.
• Centro Nacional de Farmacovigilancia (CNFV) — National Pharmacovigilance Centre, operating Mexico's pharmacovigilance database, integrated with WHO VigiBase via UMC Uppsala.
• Centro Integral de Servicios (CIS) — single-window service centre for submissions + administrative procedures.
• DIGIPRiS — COFEPRIS's digital submission portal for trámites (procedures), launched 2018 + progressively expanded.

Legal foundations are the Ley General de Salud (LGS, 1984 with extensive amendments), the Reglamento de Insumos para la Salud (RIS — Health Inputs Regulation), the Reglamento de la Ley General de Salud en Materia de Investigación para la Salud, the Reglamento de Control Sanitario de Productos y Servicios + a substantial body of Normas Oficiales Mexicanas (NOMs — official Mexican standards) covering GMP (NOM-059), medical-device QMS (NOM-241), labelling, pharmacovigilance (NOM-220) + clinical trials (NOM-012).

COFEPRIS is a PIC/S Member since January 2018, a PAHO/WHO designated Reference Regulatory Authority (NRAr) at Maturity Level IV — the highest WHO Global Benchmarking Tool level, achieved 2014 + reconfirmed 2020 + 2024. As of 2024 COFEPRIS is one of only six WHO ML4 NRAs worldwide (alongside Australia TGA, Switzerland Swissmedic, Saudi Arabia SFDA — recently confirmed + others). COFEPRIS is an ICH Observer, an IMDRF Affiliate Member, an active ICMRA participant + a founding member of the Pan American Network for Drug Regulatory Harmonization (PANDRH).

The Equivalence-Based Registration pathway (also called Reliance, Equivalencia or Article 222 BIS pathway) is COFEPRIS's flagship work-sharing mechanism, established under Article 222 BIS of the Ley General de Salud + operationalised by Acuerdo 31/01/2020 + subsequent COFEPRIS guidance. It is one of the most aggressive reliance pathways operated by any major regulator.

• Designated equivalent agencies — FDA, EMA (centralised procedure), Health Canada, TGA, Swissmedic, PMDA, MHRA + COFEPRIS-designated EU national authorities; periodically reviewed + updated.
• 60 working day clock — substantially shorter than the 240 wd Full Review for new chemical entities or 180 wd for biotechnologicals.
• Full reference-regulator dossier required — applicants provide the full assessment report, product information + supporting documentation from the reference regulator; COFEPRIS conducts a Mexican-specific overlay assessment focused on Mexican labelling, pharmacovigilance + post-marketing commitments.
• Acceptable for new MAs + Renewals + Variations — equivalence applies across the product lifecycle.
• Article 222 BIS implementation has substantially reduced approval clocks — for many companies, the equivalence pathway is the default route for entering the Mexican market.
• PANDRH harmonisation — equivalence pathway leverages PANDRH technical work + facilitates simultaneous filings in Mexico + Central American + Andean countries.
• Limitations — equivalence does not apply to controlled substances, certain biologicals + products without acceptable reference-regulator approval; full Mexican assessment is required in those cases.
• Post-equivalence variations follow the standard Modificaciones a las Condiciones de Registro framework — variation tiering applies to equivalence-approved products.
• Equivalence pathway interacts with PAHO reliance + PANDRH harmonisation — Mexican Equivalence MAs are themselves accepted by many Central + South American regulators as reliance evidence.

• Class I — Lowest risk; COFEPRIS Class I registration with reduced data requirements; many Class I devices benefit from simplified registration via DIGIPRiS.
• Class II — Moderate risk; substantively equivalent to EU MDR Class IIa / IIb with full technical + QMS evidence.
• Class III — Highest risk; substantively equivalent to EU MDR Class III with comprehensive clinical-evaluation + post-market surveillance requirements.
• IVD classification — substantively aligned with IVDR principles with COFEPRIS-specific implementation per NOM-241.
• NOM-241-SSA1-2021 — Buenas Prácticas de Fabricación de Dispositivos Médicos; Mexican QMS standard substantively aligned with ISO 13485:2016 + with COFEPRIS-specific elements.
• Reference-regulator basis — COFEPRIS recognises CE marking under EU MDR / IVDR, FDA 510(k) / De Novo / PMA, Health Canada, TGA + PMDA as evidence supporting Mexican registration via Equivalence pathway extended to devices.
• MDSAP recognition — COFEPRIS accepts MDSAP audit reports as QMS evidence; full reliance for QMS-evidence purposes.
• Mexican Responsable Sanitario — foreign manufacturers must designate a Mexican-registered Responsable Sanitario (Health Responsible) who holds professional pharmaceutical / medical credentials + handles regulatory + pharmacovigilance interactions with COFEPRIS.
• Mexican Authorised Representative + Licencia Sanitaria — required for all Mexican-resident manufacturers, importers + wholesalers; foreign manufacturers must operate through a Mexican-licensed entity.
• Clinical evaluation — Class II + III typically require Mexican clinical-investigation data or accepted reference-regulator clinical evidence; Class I may use literature + comparator data.
• Field Safety Corrective Action (FSCA) — COFEPRIS FSCA + Field Safety Notice (FSN) framework substantively aligned with EU MDR + IMDRF.
• UDI rollout — Mexico is progressively implementing UDI for medical devices following IMDRF UDI Guidance + with reference to FDA UDI + EU MDR UDI requirements.

• NOM-059-SSA1-2015 — Mexican GMP standard substantively aligned with PIC/S GMP Guide + ICH Q7 / Q9 / Q10; covers manufacture of medicinal products including biologics + APIs.
• NOM-176-SSA1-1998 — Mexican GMP standard for APIs + active pharmaceutical ingredients; complements NOM-059 + aligned with ICH Q7.
• PIC/S Member since Jan 2018 — full reliance with all PIC/S members; substantial milestone for Mexican pharma regulatory credibility.
• Reference Regulator network — COFEPRIS recognises FDA, EMA + EU national, Health Canada, TGA, MHRA, Swissmedic, PMDA + others as reference regulators for both product authorisation reliance + GMP-evidence reliance.
• Overseas inspections — COFEPRIS conducts overseas inspections of foreign sites supplying Mexico; risk-based programme prioritising new MA applications, biologics, sterile products + APIs; substantial expansion of overseas-inspection capacity since 2018.
• Data integrity — COFEPRIS data-integrity expectations substantively aligned with PIC/S PI 041 + MHRA + WHO + FDA; ALCOA+ + audit-trail + computerised-systems requirements.
• MDSAP — COFEPRIS accepts MDSAP audit reports as Mexican device QMS evidence.
• Tercero Autorizado (Third Party Authorized) — COFEPRIS-authorised Mexican entities conducting GMP audits + bioequivalence studies + clinical-trial monitoring on behalf of MAHs; controlled programme with periodic re-authorisation.
• Inspection findings + remediation — COFEPRIS Inspection Reports + Suspensión de Actividades (suspension of activities) + manufacturing-licence withdrawal; published market actions on COFEPRIS portal.
• Licencia Sanitaria — COFEPRIS-issued licences for Mexican-resident manufacturers, importers, wholesalers + retail pharmacies; required for all drug-handling activities + periodically renewed + inspected.
• GDP — Buenas Prácticas de Distribución per NOM-059 + supplementary COFEPRIS guidance; substantively aligned with PIC/S GDP Guide + EU GDP Guidelines.

• Centro Nacional de Farmacovigilancia (CNFV) — COFEPRIS pharmacovigilance unit operating Mexico's national pharmacovigilance database; integrated with WHO VigiBase via UMC Uppsala since 1999.
• NOM-220-SSA1-2016 — Mexican pharmacovigilance standard substantively aligned with ICH E2A / E2B / E2C / E2D / E2E + WHO GVP modules; covers ICSR + PSUR + RMP + signal detection.
• ICSR reporting — serious unexpected ADRs within 15 calendar days; non-serious in periodic reports + PSURs per ICH E2D + NOM-220.
• PSUR — periodic safety update reports per ICH E2C(R2); harmonised with EU + ICH PSUR cycle; submitted to CNFV.
• Risk Management Plan (RMP) — required for new active substances + biocomparables + significant indications; per ICH E2E + NOM-220.
• Responsable Sanitario para Farmacovigilancia — Mexican pharmacovigilance contact required for Mexican MAH; substantively aligned with EU QPPV role.
• Pharmacovigilance Master File — equivalent to EU PSMF for new MAs + on-request inspection availability.
• Medical device adverse-event reporting — COFEPRIS device-vigilance framework with Tecnovigilancia programme + FSCA + FSN substantively aligned with EU MDR vigilance + IMDRF.
• Healthcare-professional + consumer reporting — COFEPRIS online reporting via DIGIPRiS + Notimed mobile app + dedicated CNFV channels.
• Recall — COFEPRIS-coordinated recall framework with COS + Mexican distributors + healthcare institutions + traceability support.
• Drug Shortages — COFEPRIS drug-shortage monitoring programme; MAHs required to report shortages of essential medicines per Cuadro Básico Sectorial.
• COFEPRIS Safety Communications — Alertas Sanitarias + Notas Informativas published on COFEPRIS portal + distributed to healthcare professionals + via traditional + social media.

• PIC/S Member since Jan 2018 — full GMP reliance with all PIC/S members including FDA + EMA / EU national authorities + Health Canada + TGA + Swissmedic + PMDA + MFDS + SFDA + ANVISA + many others.
• PAHO/WHO Reference Regulatory Authority (NRAr) at Maturity Level IV — highest WHO Global Benchmarking Tool level; one of only six WHO ML4 NRAs worldwide as of 2024; reconfirmed 2014, 2020 + 2024.
• ICH Observer working toward Regulatory Membership — COFEPRIS progressively adopting ICH guidelines + participating in ICH Working Groups.
• IMDRF Affiliate Member — active on UDI, SaMD, AI / ML, QMS work products + Mexican adoption of IMDRF outputs.
• ICMRA — active member contributing on pandemic preparedness, supply chain, regulatory innovation + reliance.
• PANDRH leadership — founding member + co-leader of the Pan American Network for Drug Regulatory Harmonization; PANDRH Technical Working Groups on GMP, GCP, Pharmacovigilance, Vaccines, Biotherapeutics, Biocomparables, Medical Devices + Regulatory Reliance.
• PAHO Regional Reliance — COFEPRIS Equivalence-pathway decisions + GMP inspections are routinely accepted as reliance evidence by Central American + Andean Community regulators; COFEPRIS hosts PAHO regional training + capacity building.
• Bilateral MoUs — COFEPRIS holds MoUs with FDA, EMA, Health Canada, TGA, MHRA, Swissmedic, ANVISA, INVIMA, ANMAT + many others; tight cooperation on inspections + information exchange.
• USMCA / T-MEC alignment — Mexico's regulatory framework is influenced by USMCA pharmaceutical + medical-device provisions; tri-lateral coordination with FDA + Health Canada through trade + regulatory mechanisms.
• Vaccines + COVID-19 response — COFEPRIS Emergency Use Authorization framework + accelerated review for COVID-19 vaccines + therapeutics demonstrated PIC/S-Member-level capability; COVAX participation + WHO vaccine programmes.

• Responsable Sanitario not properly designated or credentialed — application rejected at DIGIPRiS intake or post-approval compliance failure.
• Licencia Sanitaria not in place or scope mismatched — market placement blocked.
• Equivalence pathway eligibility misjudged — applicants applying for Equivalence with non-designated reference regulator or incomplete reference dossier; clock reverts to Full Review.
• Spanish-language labelling + IFU non-compliant — Mexican labelling requires Spanish + specific COFEPRIS-required content + warnings + Responsable Sanitario contact details + Cuadro Básico identification.
• DIGIPRiS eCTD submission errors — module structure non-compliance, missing Module 1 Mexican-specific elements, technical-format failures.
• Tercero Autorizado bioequivalence study quality issues — bioequivalence study at non-authorised centre or with methodology deficiencies; generic registration delayed or rejected.
• NOM-220 pharmacovigilance reporting timelines missed — Responsable Sanitario para Farmacovigilancia enforcement.
• Data integrity findings — backdating, audit-trail disabled, shared logins, uncontrolled spreadsheets used as raw data; PIC/S-level expectations apply post-2018.
• Sterile / aseptic process gaps — COFEPRIS inspectorate alignment with EU GMP Annex 1 (2022 revision) creates new expectations + frequent findings.
• MDSAP audit-report packaging gap — COFEPRIS accepts MDSAP but requires the full audit report + non-conformity closures.
• NOM-241 device QMS gaps — Mexican-specific elements beyond ISO 13485 not addressed.
• Clinical-trial CTA + Comité de Ética en Investigación coordination gap per NOM-012.
• Variations tier misclassification — applicants treating major variations as minor; rework + clock reset.
• Cuadro Básico Sectorial misalignment — products targeting Mexican public-sector procurement (IMSS, ISSSTE, INSABI) without proper Cuadro Básico listing.
• PSUR not aligned with International Birth Date — Mexican PSUR cycle out of sync with EMA PSUR / FDA PADER submissions.

V5 Ultimate provides the operational infrastructure Mexican + foreign-supplier sites need for LGS + RIS + NOM-059 + NOM-241 + NOM-220 + COFEPRIS Implementing guidance compliance + COFEPRIS readiness.

• COFEPRIS GMP control framework — PIC/S-aligned controls (clean rooms, aseptic process, environmental monitoring, EU GMP Annex 1 2022 alignment, computerised systems) with ALCOA+ data-integrity + COFEPRIS data-integrity-expectation alignment.
• Responsable Sanitario + Licencia Sanitaria workflow — Responsable Sanitario designation + credential tracking, Licencia Sanitaria scope management, foreign-manufacturer QMS-evidence packaging.
• DIGIPRiS submission packaging — eCTD-aligned dossier structure with Mexican Module 1 specifics, reference-regulator assessment-report packaging for Equivalence pathway.
• Equivalence pathway workflow — reference-regulator assessment-report packaging, designated-agency eligibility verification, Mexican-specific overlay assessment, 60-wd clock tracking.
• Reference-regulator bridging — FDA / EMA / Health Canada / TGA / MHRA / Swissmedic / PMDA assessment-report packaging for COFEPRIS Equivalence pathway; Mexican-specific data overlay.
• Medical Device + IVD registration workflow — Class I / II / III + IVD classification, MDSAP + ISO 13485 + NOM-241 audit-report packaging, COFEPRIS device-registration tracking.
• Tercero Autorizado management — bioequivalence study + GMP audit + clinical-monitoring engagement workflow with COFEPRIS-authorised third parties.
• Spanish + bilingual labelling + IFU — Mexican-language artwork workflow with two-person review + e-signature; COFEPRIS-required elements + warnings + storage conditions + Responsable Sanitario details + Cuadro Básico identification.
• CNFV pharmacovigilance — E2B(R3) ICSR generation, 15-day SUSAR timeline, PSUR / RMP packaging, Responsable Sanitario para Farmacovigilancia workflow + Mexican Pharmacovigilance Master File.
• Medical device tecnovigilancia — FSCA + FSN reporting per COFEPRIS framework + IMDRF alignment.
• PANDRH + PAHO regional bridging — for companies operating across Latin America, V5 surfaces COFEPRIS-decision reuse + PANDRH-harmonised dossier elements + Central American + Andean Community filing workflows.
• Cuadro Básico Sectorial — for products targeting Mexican public-sector procurement (IMSS, ISSSTE, INSABI), V5 surfaces Cuadro Básico listing workflow + public-procurement tender preparation.